tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Developments and Positive Trial Results Reinforce Buy Rating for OnKure Therapeutics
PremiumRatingsPromising Developments and Positive Trial Results Reinforce Buy Rating for OnKure Therapeutics
2M ago
OnKure Therapeutics Reports Q1 2025 Progress and Financials
Premium
Company Announcements
OnKure Therapeutics Reports Q1 2025 Progress and Financials
2M ago
OnKure Therapeutics reports Q1 EPS ($1.19), consensus ($1.38)
Premium
The Fly
OnKure Therapeutics reports Q1 EPS ($1.19), consensus ($1.38)
3M ago
Oppenheimer biotech analyst holds an analyst/industry conference call
PremiumThe FlyOppenheimer biotech analyst holds an analyst/industry conference call
4M ago
Optimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future Prospects
Premium
Ratings
Optimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future Prospects
4M ago
Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies
Premium
Company Announcements
Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies
4M ago
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
PremiumThe FlyCantor Fitzgerald biotech analysts hold an analyst/industry conference call
7M ago
OnKure Therapeutics Advances Cancer Drug Trials
Premium
Company Announcements
OnKure Therapeutics Advances Cancer Drug Trials
7M ago
OnKure Therapeutics announces safety, pharmacokinetic data on OKI-219
Premium
The Fly
OnKure Therapeutics announces safety, pharmacokinetic data on OKI-219
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100